Kai Li

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 620 citations · Full text

Medicine, Oncology, Pharmacology +17

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao et al. · British Journal of Cancer · 2018 · 263 citations · Full text

Medicine, Oncology, Pharmacology +16

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

Shaochuan Liu, Tingting Qin, Zhujun Liu et al. · Cell Death and Disease · 2020 · 186 citations · Full text

Medicine, Immunology, Oncology +17

Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant

Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo et al. · JAMA · 2024 · 168 citations · Full text

Medicine, Oncology, Pharmacology +16

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Ying Cheng, Qiming Wang, Kai Li et al. · British Journal of Cancer · 2021 · 147 citations · Full text

Medicine, Oncology, Pharmacology +9